ES2987376T3 - Composiciones terapéuticas, combinaciones y métodos de uso - Google Patents

Composiciones terapéuticas, combinaciones y métodos de uso Download PDF

Info

Publication number
ES2987376T3
ES2987376T3 ES16818676T ES16818676T ES2987376T3 ES 2987376 T3 ES2987376 T3 ES 2987376T3 ES 16818676 T ES16818676 T ES 16818676T ES 16818676 T ES16818676 T ES 16818676T ES 2987376 T3 ES2987376 T3 ES 2987376T3
Authority
ES
Spain
Prior art keywords
cancer
defactinib
administered
tumor
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16818676T
Other languages
English (en)
Spanish (es)
Inventor
Jonathan Pachter
Jennifer Ring
David Weaver
Yan Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Verastem Inc
Original Assignee
Verastem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verastem Inc filed Critical Verastem Inc
Application granted granted Critical
Publication of ES2987376T3 publication Critical patent/ES2987376T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES16818676T 2015-06-29 2016-06-29 Composiciones terapéuticas, combinaciones y métodos de uso Active ES2987376T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562186197P 2015-06-29 2015-06-29
PCT/US2016/040080 WO2017004192A1 (en) 2015-06-29 2016-06-29 Therapeutic compositions, combinations, and methods of use

Publications (1)

Publication Number Publication Date
ES2987376T3 true ES2987376T3 (es) 2024-11-14

Family

ID=57609144

Family Applications (1)

Application Number Title Priority Date Filing Date
ES16818676T Active ES2987376T3 (es) 2015-06-29 2016-06-29 Composiciones terapéuticas, combinaciones y métodos de uso

Country Status (13)

Country Link
US (3) US10532056B2 (https=)
EP (2) EP3313404B1 (https=)
JP (3) JP2018519327A (https=)
KR (1) KR102783581B1 (https=)
CN (2) CN114209841A (https=)
AU (3) AU2016286091B2 (https=)
CA (2) CA3244408A1 (https=)
EA (1) EA201890161A1 (https=)
ES (1) ES2987376T3 (https=)
IL (2) IL256652B2 (https=)
MX (2) MX389683B (https=)
WO (1) WO2017004192A1 (https=)
ZA (1) ZA201800572B (https=)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015008844A1 (ja) 2013-07-18 2015-01-22 大鵬薬品工業株式会社 Ｆｇｆｒ阻害剤耐性癌の治療薬
TR201907147T4 (tr) 2013-07-18 2019-06-21 Taiho Pharmaceutical Co Ltd Fgfr inhibitörünün aralıklı uygulanmasına yönelik anti-tümör ilaç.
SG10201805890QA (en) * 2014-01-09 2018-08-30 Verastem Inc Compositions and methods for treatment of abnormal cell growth
CN108112254B (zh) 2015-03-13 2022-01-28 西托姆克斯治疗公司 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
CN114591433A (zh) 2015-07-13 2022-06-07 西托姆克斯治疗公司 抗pd-1抗体、可活化抗pd-1抗体及其使用方法
JP6823067B2 (ja) 2015-09-10 2021-01-27 タンボ・インコーポレイテッド 生体直交型組成物
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
EP3424505A4 (en) 2016-03-04 2019-10-16 Taiho Pharmaceutical Co., Ltd. PREPARATION AND COMPOSITION FOR THE TREATMENT OF MALIGNANT TUMORS
UY37594A (es) 2017-02-07 2018-08-31 Univ Saitama Medical Biomarcador inmunologico para predecir el efecto clinico de inmunoterapia del cancer
ES2983582T3 (es) 2017-04-07 2024-10-23 Tambo Inc Composiciones bioortogonales
JP2020522486A (ja) 2017-06-01 2020-07-30 サイトメックス セラピューティクス インコーポレイテッド 活性化可能抗ｐｄｌ１抗体、およびその使用方法
US11452764B2 (en) * 2017-07-21 2022-09-27 University Of North Dakota Inhibiting FAK-AKT interaction to inhibit metastasis
JP2021517589A (ja) * 2018-03-12 2021-07-26 アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） 癌の治療のための化学免疫療法を増強するためのカロリー制限模倣物の使用
SG11202008435SA (en) 2018-03-19 2020-10-29 Taiho Pharmaceutical Co Ltd Pharmaceutical composition including sodium alkyl sulfate
CN110960679A (zh) * 2018-09-28 2020-04-07 江苏康缘药业股份有限公司 一种抗肿瘤的药物组合物及其应用
WO2020135442A1 (zh) * 2018-12-27 2020-07-02 成都海创药业有限公司 一种fak抑制剂及其联合用药物
CN109675040B (zh) * 2018-12-31 2021-07-30 清华大学 治疗乳腺癌的组合物及其应用
EP3928792A4 (en) 2019-02-20 2022-12-14 Saitama Medical University BIOMARKERS IN PERIPHERAL BLOOD FOR ASSESSING THE ANTI-TUMORS IMMUNE EFFECT OF RADIATION THERAPY
MA55088A (fr) * 2019-02-28 2022-01-05 Taiho Pharmaceutical Co Ltd Cancérothérapie utilisant un composé d'alcynyle benzène 3,5-disubstitué et un inhibiteur de point de contrôle immunitaire
WO2020202005A1 (en) * 2019-04-02 2020-10-08 Inxmed (Shanghai) Co., Ltd. Combination of a fak kinase inhibitor and an agent targeting t-cell co-stimulatory receptors
TWI757716B (zh) * 2019-04-15 2022-03-11 禾榮科技股份有限公司 微創型中子束產生裝置及微創型中子捕獲治療系統
JP7199523B2 (ja) 2019-05-10 2023-01-05 富士フイルム株式会社 光照射装置およびセンサー
CN110201171A (zh) * 2019-06-18 2019-09-06 北京大学 Fak抑制剂在治疗常染色体显性遗传多囊肾病中的应用
CN114641310A (zh) * 2019-06-21 2022-06-17 德克萨斯大学系统董事会 治疗癌症和其他疾病的靶向α3β1整合素
AU2020310853A1 (en) * 2019-07-05 2022-01-27 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
WO2021047783A1 (en) * 2019-09-13 2021-03-18 The Institute Of Cancer Research: Royal Cancer Hospital Vs-6063 in combination with ch5126766 for the treatment of cancer
AU2020388848A1 (en) * 2019-11-18 2022-05-26 Inxmed (Nanjing) Co., Ltd. Use of FAK inhibitor in preparation of drug for treating tumors having NRAS mutation
MY209389A (en) * 2019-11-28 2025-07-07 Inxmed Nanjing Co Ltd Use of bi853520 in cancer treatment
CN115279376A (zh) * 2020-01-31 2022-11-01 维瑞斯特姆股份有限公司 用于治疗异常细胞生长的组合疗法
MX2022009612A (es) 2020-02-05 2022-09-19 Inxmed Nanjing Co Ltd Combinacion de bi853520 con farmacos quimioterapeuticos.
JP7470775B2 (ja) 2020-02-14 2024-04-18 富士フイルム株式会社 光結合システムおよび光通信デバイス
AU2021307410A1 (en) * 2020-07-13 2023-02-09 Verastem, Inc. Combination therapy for treating abnormal cell growth
TW202206425A (zh) * 2020-08-03 2022-02-16 大陸商應世生物科技（南京）有限公司 化合物的固體形式
EP4295917A3 (en) 2020-08-07 2024-02-28 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
WO2022125652A1 (en) * 2020-12-08 2022-06-16 Cornell University Methods of inducing an immunomodulatory tumor response
EP4259123A4 (en) * 2020-12-11 2024-11-20 Materia Therapeutics Inc. TREATMENT OF CANCER USING BOSENTAN IN COMBINATION WITH A CHECKPOINT INHIBITOR
TW202313044A (zh) 2021-08-16 2023-04-01 大陸商應世生物科技（南京）有限公司 Ｉｎ１００１８與ｐｌｄ的聯用
JP2024545147A (ja) * 2021-12-10 2024-12-05 ▲應▼世生物科技（南京）有限公司 腫瘍治療の医薬組合せ及び使用
CN116889565A (zh) * 2022-04-07 2023-10-17 深圳微芯生物科技股份有限公司 西奥罗尼在抗胰腺癌中的用途
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor
WO2023246869A1 (zh) * 2022-06-24 2023-12-28 应世生物科技(南京)有限公司 治疗肿瘤的药物组合及用途
KR20250052367A (ko) * 2022-08-24 2025-04-18 인엑스메드 (난징) 컴퍼니 리미티드 Fak 억제제와 미세소관 억제제의 약제학적 병용물 및 이의 용도
CN119816326A (zh) * 2022-09-05 2025-04-11 应世生物科技(南京)有限公司 Fak抑制剂及egfr-tki的药物组合及用途
TW202412766A (zh) * 2022-09-16 2024-04-01 大陸商應世生物科技（南京）有限公司 Ｆａｋ抑制劑及拓撲異構酶抑制劑的藥物組合及用途
CN119947725A (zh) * 2022-09-30 2025-05-06 应世生物科技(南京)有限公司 Fak抑制剂及诱导免疫原性细胞死亡的物质的药物组合及用途
AU2024211503A1 (en) * 2023-01-24 2025-07-31 Msd International Business Gmbh Methods and compositions for combination therapy

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607683D0 (en) 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
US20030009158A1 (en) 2001-07-09 2003-01-09 Perricone Nicholas V. Skin treatments using blue and violet light
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US20040197312A1 (en) * 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
FI20030976A7 (fi) 2003-06-30 2004-12-31 M Real Oyj Päällystetty pohjapaperi ja menetelmä päällystetyn pohjapaperin valmistamiseksi
ATE534301T1 (de) 2004-06-30 2011-12-15 Cadbury Holdings Ltd Kaugummi mit aromastoffemulsion
BRPI0720264B1 (pt) * 2006-12-08 2022-03-03 Novartis Ag Compostos e composições como inibidores de proteína cinase
DK2134689T3 (da) 2007-03-16 2014-06-30 Scripps Research Inst Inhibitorer af fokal adhæsionskinase
BRPI0810411B8 (pt) 2007-04-18 2021-05-25 Pfizer Prod Inc derivados de sulfonil amida para o tratamento de crescimento celular anormal, seu sos, bem como composição farmacêutica
WO2009105498A1 (en) 2008-02-19 2009-08-27 Smithkline Beecham Corporation Anilinopyridines as inhibitors of fak
MX2010014057A (es) 2008-06-17 2011-03-21 Astrazeneca Ab Compuestos de piridina.
JO3067B1 (ar) 2008-10-27 2017-03-15 Glaxosmithkline Llc بيرميدينات بيرازولو امينو كمثبطات ل fak
US20140155410A1 (en) 2008-10-27 2014-06-05 Glaxosmithkline Llc Pyrazolylaminopyridines as inhibitors of fak
WO2012045194A1 (en) * 2010-10-09 2012-04-12 Abbott Laboratories Benzodiazepinones as fak inhibitors for treatment of cancer
RU2014102595A (ru) * 2011-06-28 2015-08-20 Глэксосмитклайн Интеллекчуал Проперти (No.2) Лимитед Способ введения и лечения
EP2903644A4 (en) * 2012-10-05 2016-03-09 Cerulean Pharma Inc TREATMENT OF CANCER
WO2015061796A1 (en) 2013-10-25 2015-04-30 Nodality Inc. Methods and compositions for immunomodulation
JP2016535989A (ja) * 2013-11-01 2016-11-24 ファイザー・インク 前立腺関連抗原を発現させるためのベクター
ES2779975T3 (es) * 2014-02-07 2020-08-21 Verastem Inc Métodos y composiciones para tratar el crecimiento celular anormal
WO2017201043A1 (en) 2016-05-16 2017-11-23 Concert Pharmaceuticals, Inc. Combination therapy for treating cancer

Also Published As

Publication number Publication date
EP3313404B1 (en) 2024-09-04
AU2023214272A1 (en) 2023-08-31
JP2024111247A (ja) 2024-08-16
ZA201800572B (en) 2023-12-20
AU2023214272B2 (en) 2025-08-14
BR112017028519A2 (en) 2018-08-28
US20180177788A1 (en) 2018-06-28
EA201890161A1 (ru) 2018-06-29
EP3313404C0 (en) 2024-09-04
NZ739490A (en) 2024-11-29
JP2018519327A (ja) 2018-07-19
CA2991044C (en) 2024-11-19
US20240000790A1 (en) 2024-01-04
JP2021183650A (ja) 2021-12-02
WO2017004192A1 (en) 2017-01-05
AU2016286091A1 (en) 2018-02-22
US10532056B2 (en) 2020-01-14
IL256652B2 (en) 2026-03-01
MX2018000288A (es) 2018-11-09
AU2021202379A1 (en) 2021-05-13
NZ777396A (en) 2025-03-28
EP4488265A2 (en) 2025-01-08
IL322086A (en) 2025-09-01
CN108289892A (zh) 2018-07-17
CA3244408A1 (en) 2025-06-13
EP3313404A4 (en) 2019-08-07
CN108289892B (zh) 2021-11-23
US20200330471A1 (en) 2020-10-22
KR102783581B1 (ko) 2025-03-17
US11564927B2 (en) 2023-01-31
IL256652B1 (en) 2025-11-01
MX2022001165A (es) 2022-02-22
KR20180100539A (ko) 2018-09-11
IL256652A (en) 2018-02-28
AU2021202379B2 (en) 2023-05-11
HK1254525A1 (en) 2019-07-19
CN114209841A (zh) 2022-03-22
CA2991044A1 (en) 2017-01-05
EP4488265A3 (en) 2025-04-02
AU2016286091B2 (en) 2021-02-04
MX389683B (es) 2025-03-20
EP3313404A1 (en) 2018-05-02

Similar Documents

Publication Publication Date Title
ES2987376T3 (es) Composiciones terapéuticas, combinaciones y métodos de uso
JP7578643B2 (ja) 異常な細胞成長を処置するための方法および組成物
CN114630667A (zh) 用于治疗癌症的vs-6063与ch5126766的组合
JP2022172480A5 (https=)
KR20240041978A (ko) 비정상적 세포 성장을 치료하기 위한 조합 요법
HK40121585A (en) Therapeutic compositions, combinations, and methods of use
HK1254525B (en) Therapeutic compositions, combinations, and methods of use
BR112017028519B1 (pt) Uso de defactinibe na preparação de um medicamento para tratamento de câncer
EA042150B1 (ru) Терапевтические композиции, комбинации и способы применения
HK40075762A (en) Vs-6063 in combination with ch5126766 for the treatment of cancer
WO2016109426A1 (en) Oral dosing regimen of a dual mtor and pi3 inhibitor